| Pre-trial and concomitant use of drugs and clinical outcomes in the XAMOS study* | ||
|---|---|---|
| Rivaroxaban (%) | SOC (%) | |
| Pretrial use (≤7 days before surgery) | ||
| CYP3A4 inhibitors | 2.3 | 3.0 |
| CYP3A4 inducers | 0.8 | 0.8 |
| PAIs | 6.8 | 8.2 |
| Concomitant use during the study | ||
| CYP3A4 inhibitors | 0.5 | 1.0 |
| CYP3A4 inducers | 0.4 | 0.7 |
| PAIs | 2.8 | 3.7 |
| Incidence of any symptomatic thromboembolic events | ||
| Concomitant use of PAIs | 2.4 | 4.0 |
| No concomitant use of PAIs | 0.6 | 0.9 |
| Incidence of any treatment-emergent bleeding events | ||
| Concomitant use of PAIs | 8.4 | 8.1 |
| No concomitant use of PAIs | 4.6 | 3.0 |
↵* Unadjusted data as crude estimates for comparison between groups (covariate-adjusted and propensity score-adjusted results will be presented elsewhere upon completion of the final data analyses).